Cantor Fitzgerald Inc.: Reiterated the Intra-Cellular Therapies (ITCI.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $120.00.
Zhitong FinanceApr 24 22:01
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
BenzingaApr 24 21:57
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
TipRanksApr 24 20:50
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 23 22:48
Canadian Investment Banking Group: Maintaining the Intra-Cellular Therapies (ITCI.US) rating, adjusted from buy to buy rating, and adjusted the target price from $100.00 to $107.00.
Zhitong FinanceApr 23 22:51
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107
BenzingaApr 23 22:49
Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market
TipRanksApr 22 22:05
Mizuho Bank: Maintaining the Intra-Cellular Therapies (ITCI.US) rating, adjusted from buy to buy rating, and adjusted the target price from $82.00 to $96.00.
Zhitong FinanceApr 22 19:21
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 22 19:10
Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $96
BenzingaApr 22 19:11
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
TipRanksApr 19 09:50
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)
TipRanksApr 18 20:20
TD Cowen: Maintaining the Intra-Cellular Therapies (ITCI.US) rating, adjusted from buy to buy rating, and adjusted the target price from $80.00 to $90.00.
Zhitong FinanceApr 17 18:20
Intra-Cellular Therapies Analyst Ratings
BenzingaApr 17 18:14
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Intra-Cellular Therapies (ITCI)
TipRanksApr 17 17:20
Intra-Cellular Therapies: Hold Rating With Increased Price Target Amid Caplyta's Clinical Success
TipRanksApr 17 03:45
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)
TipRanksApr 16 20:11
Needham: Reiterated the Intra-Cellular Therapies (ITCI.US) rating and adjusted from buy to buy rating, target price of $82.00.
Zhitong FinanceApr 16 20:02
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
TipRanksApr 5 19:00
Intra-Cellular Therapies Buy Rating: High Confidence in Caplyta's Success for MDD Treatment
TipRanksApr 5 17:25
No Data
No Data